The crystal structure of a post-translationally modi®ed form of eosinophil-derived neurotoxin (EDN) with four extra residues on its N terminus ((À4)EDN) has been solved and re®ned at atomic resolution (1 A Ê ). Two of the extra residues can be placed unambiguously, while the density corresponding to two others is poor. The modi®ed N terminus appears to in¯uence the position of the catalytically important His129, possibly explaining the diminished catalytic activity of this variant. However, (À4)EDN has been shown to be cytotoxic to a Kaposi's sarcoma tumor cell line and other endothelial cell lines. Analysis of the structure and function suggests that the reason for cytotoxicity is most likely due to cellular recognition by the N-terminal extension, since the intrinsic activity of the enzyme is not suf®cient for cytotoxicity and the N-terminal extension does not affect the conformation of EDN.
Introduction
Biological actions reported for human ribonucleases (RNases) homologous to RNase A range from the causation of neurological symptoms in animal models to host defense actions and neovascularization. 1 ± 3 Human RNases present therapeutic opportunities for cancer and viral diseases. Eosinophil-derived neurotoxin (EDN) is one of the major proteins present in the granules of eosinophils. Recent results indicate that EDN may possess activity directed against respiratory syncytial virus (RSV) through direct inhibition of RSV replication. 4 These results led to the hypothesis that RNases have evolved antiviral host defense activity.
A novel post-translationally modi®ed form of EDN (called (À4)EDN) contains amino acid residues À4 to À1 of the EDN signal peptide. 5 The post-translationally modi®ed (À4)EDN was reported to inhibit oocyte maturation 5 and to be present predominantly in pregnant women. 6 The À4 to À1 amino acid sequence (SLHV) resembles a peptide reported to recognize Kaposi's sarcoma (KS) tumors in vivo. 7 EDN genetically modi®ed to express the four amino acid extension was cytotoxic to an endothelial-like KS cell-line (KS Y-1) 8 and other endothelial cell lines. 9 Since small peptides can target drugs, 7 the four amino acid peptide extension might act as a recognition motif for a receptor-like molecule on some cells, effectively targeting EDN to that cell. It may be responsible for some of the anti-KS activity 8 previously associated with a human pregnancy hormone (hCG). 10 A crystal structure of the native form of EDN has been reported at 1.83 A Ê resolution, 11 although the coordinates resulting from that work have not been made publicly available. More recently, structures of three complexes of that enzyme with nucleotides, as well as of EDN with only a sulfate ion bound in the active site, were published at 1.8-1.6 A Ê resolution. 12 The studies reported here provide the ®rst glimpse at this enzyme at an atomic resolution, and compare the enzymatic and biological activities of the native enzyme and its extended form.
Results and Discussion
Diffraction data for (À4)EDN were collected using synchrotron radiation at 1 A Ê resolution ( Table 1 ). The structure was solved by molecular replacement using the coordinates of EDN as the starting model. 11 The structure was re®ned with the application of anisotropic temperature factors and the ®nal coordinates discussed below, as well as the structure factors, have been deposited with the Protein Data Bank (see Materials and Methods).
Assessment of the quality of the refined structure
The ®nal re®ned model of (À4)EDN contains 136 amino acid residues, two sulfate ions, and 244 water molecules. The R-value for all re¯ections in the 20.0-1.0 A Ê range is 13.2 % (R free of 16.9 %). The re®nement statistics are summarized in Table 2 . All residues except for glycine or proline lie either in the most-favored or in additionally allowed regions of the Ramachandran plot. 13 The electron density map is very clear, except in the N-terminal region and in a few¯exible regions. The ®rst residue that can be traced unambiguously is His À2. Although weak density appeared on the amino side of this residue, the peptide bond between residues À3 and À2 is energetically unfavorable in the Ramachandran plot when the main chain for residues À4 to À2 was built along that density. Thus, the ®rst two residues were not included in the ®nal model, which consists of the uninterrupted chain extending from His À2 to Ile134. Besides at the N terminus, the electron density map in the vicinity of Lys66 and Gln91 is not clear (reasonably well de®ned for the main chain, but absent for the sidechain atoms). These residues are located in rather exible regions, as judged by their comparatively high temperature factors. The average B-factors of the main-chain atoms for residues Ser64, Asn65, Lys66, Pro90, Gln91, Asn92 are 27.0 A Ê 2 , 34.0 A Ê 2 , 32.5 A Ê 2 , 31.0 A Ê 2 , 37.0 A Ê 2 , and 29.5 A Ê 2 , respectively, whereas the respective average B-factors of the side-chain atoms for these residues are 32.7 A Ê 2 , 49.2 A Ê 2 , 73.4 A Ê 2 , 39.7 A Ê 2 , 70.2 A Ê 2 , and 47.6 A Ê 2 . In the structure of RNase A, the residue corresponding to Asn65 in (À4)EDN is Asn67. That residue can be deamidated easily under mild conditions and converted to iso-Asp, and it was shown to be highly¯exible in the ultrahigh-resolution structure of RNase A.
14 The B-factor for the C-terminal residue Ile134 is also high. The electron density map for the main-chain atoms of that residue is de®ned well, but not very clear for the side-chain atoms, especially CD1 and CG2.
Overall structure and multiple conformations of the side-chains
The overall structure of (À4)EDN is virtually the same as that of EDN. When C a atoms for (À4)EDN and EDN (PDB accession code 1HI2 12 ) are superimposed, the r.m.s. deviation is 0.29 A Ê . The overall shape of (À4)EDN shows the typical RNase fold, which is a V-shaped a b-type polypeptide with the active-site cleft in the middle. The secondary structure elements correspond to those described for EDN, consisting of six b strands and four a helices (including one 3 10 helix). The structure of (À4)EDN is organized into two lobes with the two N-terminal a helices (a1 and a2) located between them. Strands b1, b3, and b4 create an anti-parallel b sheet in one of the lobes, and a 3 10 helix between b3 and b4 belongs to the same lobe. The other lobe is composed of the helix a3 and an anti-parallel b sheet composed of strands b2, b5, and b6 ( Figure 1 ). EDN and (À4)EDN contain four disul®de bonds.
An interesting feature of this atomic-resolution structure is a large number of residues for which alternative conformations of their side-chains can be assigned. Such alternative conformations can be seen clearly for 18 residues (Table 3) . By comparison, the structure of phosphate-free bovine pancreatic RNase A solved at 1.26 A Ê resolution shows c For protein atoms, the B-factor was averaged for all atoms, including hydrogen atoms.
13 residues with alternative conformations. 15 However, the residues with multiple conformations are quite different in these two enzymes. In (À4)EDN, such residues are distributed evenly throughout the molecule. The two alternative conformations of Gln40 and His82 are correlated in the same mol- Temperature factors are averaged for all atoms belonging to each alternate conformation.
Structure and Activity of (À4)EDN ecule, while crystallographic contacts are responsible for the correlation between the alternative conformations of Phe5 and Gln22 ( Figure 2 ).
One of the residues observed in two conformations is the active-site His129 (corresponding to His119 in RNase A). Several crystallographic stu- Table 2 .
dies of the latter enzyme have reported two distinct conformations for His119, 14, 16 and the two conformations of His129 in (À4)EDN are closely similar to those in RNase A ( Figure 2 ). As discussed further below, only one of these conformations agrees with the postulated enzymatic mechanism for this family of enzymes, while the second one is probably transient and does not support enzymatic activity. 17 For several other residues, the density for the alternative conformation is not ideal, but if only one conformation was included in the re®nement, the resulting F o À F c map showed signi®cant peaks that could not be due to solvent, since they were much too close to the protein chain. Examples of such residues are Asn25, Asn32, Gln40, Arg68, and His82.
Substrate-binding pocket and the active-site residues
Since the recently solved structures of nucleotide complexes of EDN 12 were not available when the work described here was underway, the structure of a putative complex of (À4)EDN with a substrate was modeled (Figure 3 ) on the basis of the inactive conformation of RNase A as seen in the complex with (Tp) 4 (PDB accession code 1RTA 18 ). The cleavage site of this substrate lies between nucleotides T3 and T4. In the (À4)EDN/substrate model, His À2, Arg36, and His129 seem to interfere with the binding of the substrate. His À 2 and His129 are in contact with the base of T4. For the RNase A family, the structure with a sulfate ion shows that the side-chain of His129 (119 in RNase A) occupies that space. 14, 16 Side-chain atoms of Arg36 (Arg39 in RNase A) occupy the same space as the phosphate group of T1. Since the arginine sidechain can be¯exible and thus be pushed away from the catalytic center, we may conclude that Arg36 is most likely not critical for substrate binding and should not affect reaction kinetics. The backbone atoms of Arg36 are located in the same area as in the RNase/substrate complex structure.
Two sulfate ions were found in the structure of (À4)EDN, and their locations are in agreement with the data reported recently for EDN with a sulfate ion bound in the active site. 12 Both of these sulfate ions are located in the substrate-binding pocket. Sul151 is conserved in the structures of other RNases and shows a hydrogen-bonding pattern similar to that of a T4 phosphate group in the complex discussed above. This sulfate ion makes hydrogen bonds with His15, His129, and the amide nitrogen atom of Leu130. For His129, both the``active'' and the``inactive'' conformations make hydrogen bonds with the sulfate ion. Besides these protein residues, four more water molecules interact with this sulfate ion. Sul152 is conserved in the EDN structures, but has not been found in the corresponding structures of RNAse A. Sul152 does not show any special relationship to the substrate as de®ned above. This sulfate ion makes hydrogen bonds with the side-chain nitrogen atoms of Arg36 and Asn39B, while it does not make hydrogen bonds with Asn39A. The side-chain amide group of Gln40 also makes a hydrogen bond with Sul152. These hydrogen bonds are conserved in all sulfatebinding EDN structures.
The active-site residues of (À4)EDN include His15, Lys38, and His129 (His12, Lys41, and His119 in RNase A, respectively) and all of them are strictly conserved in RNase A. In the structures Figure 3 . The active site of (À4)EDN. Active-site residues are presented in red, the substrate model is in blue, and His À 2 is shown in magenta. Only the residues T3 and T4 of the substrate are displayed in the active site of the enzyme.
Structure and Activity of (À4)EDN of RNase A, His119 has been reported in two conformations, denoted A (w 1 % 150
) and B (w 1 % À 60 ). Conformation A is compatible with nucleotide binding, 19 ± 21 whereas low pH or the presence of sulfate/phosphate in the active site favors conformation B.
14,22 The high-resolution structure of (À4)EDN contains both of these conformations of His129. The occupancy of conformation B is 0.61 with an average B-factor of 16.2 A Ê 2 , whereas the occupancy of conformation A is 0.39 with an average B-factor of 16.6 A Ê 2 .
The residues that extend the N-terminal section of (À4)EDN are located near the active site of the enzyme. His À 2 is oriented toward the active site, while the additional N-terminal residues surround the substrate-binding pocket (Figure 3 ). His À 2 interacts with the catalytically important His129. This interaction might affect the relative occupancy of both observed conformations of His129 and thus explain the reduced enzymatic activity of (À4)EDN (see below). The side-chain of His À 2 is stabilized by this interaction and shows well-de®ned electron density, while the density corresponding to the ®rst two residues (Ser À 4, Leu À 3) was so poor that we did not attempt to model them.
Enzymatic activity
The enzymatic activity of (À4)EDN was compared to that of EDN (Table 4) . While the af®nities of both enzymes for a substrate were similar (K m 12.8 and 15.3 mM for EDN and (À4)EDN, respectively), the catalytic ef®ciency of (À4)EDN was only 8 % that of EDN (K cat /K m ratio 3.2 Â 10 6 M À1 s À1 versus 2.5 Â 10 5 M À1 s À1 , EDN and (À4)EDN, respectively). The pH pro®les of both enzymes were the same (not shown) and the optimal enzymatic activity was achieved at pH 7.5. Placental ribonuclease inhibitor (RI) inhibits a wide variety of pancreatic-type RNases 23 and we could con®rm that the RNase activity of both EDN and (À4)EDN was inhibited by RI (Figure 4) . Thus, appending four amino acid residues to the N terminus of EDN does not affect the pH at which ribonuclease activity is maximal, inhibition by RI, or the af®nity of the enzyme for the substrate. However, the catalytic ef®ciency of the enzyme is diminished by an order of magnitude.
Binding of EDN and (À4)EDN to KS Y-1 cells
Previously, (À4)EDN was shown to inhibit the cell viability of KS Y-1 cells markedly, while EDN had no effect on viability.
8 KS Y-1 cells are a Kaposi's sarcoma-derived cell line. 24 The reported values of IC 50 were 6 mg/ml and >100 mg/ml for (À4)EDN and EDN, respectively. Human pancreatic type RNases are generally not cytotoxic to cultured cells, but are as potent as toxins when injected into cells directly. 25 This one and other studies 26 indicate that transmembrane transport is rate-limiting for the expression of cytotoxicity by RNases. Moreover, peptides can bind to speci®c sites in order to deliver drugs. 7 Therefore, the possibility that the SLHV peptide could deliver EDN to an intracellular target by altering binding and internalization was investigated. C in the presence or absence of the respective unlabeled proteins. Binding of (À4)EDN was saturable ( Figure 5(a) ). In contrast, the binding of EDN did not appear to be saturable and continued to rise even at the highest concentration tested (1000 nM, Figure 5(b) ). Interestingly, although the speci®c activities of the two RNases were similar (2.0 Â 10 6 cpm/mg and 2.6 Â 10 6 cpm/mg for EDN and (À4)EDN, respectively), the amount of radioactivity associated with the cell was approximately three-to fourfold higher for EDN than for (À4)EDN. Scatchard analysis of the saturable (À4)EDN binding indicated that it bound to cells with a K D of about 1 mM. This is close to the lowaf®nity binding reported for onconase on 9L glioma cells (0.25 mM
26
). Onconase is similar to other amphibian members of the pancreatic RNase A family that possess inherent cytotoxicity. 27 Cell-surface binding and internalization are involved in onconase cytotoxicity and, although the nature of the onconase receptor is not known, 28 we reasoned that the SLHV peptide might recognize a binding site similar to that of onconase. Competition binding experiments support this supposition, as onconase competed effectively for binding of (Figure 6 ). Binding of 50 nM and 500 nM radiolabeled (À4)EDN was also decreased (Figure 6 ). Although binding of radiolabeled EDN was decreased in the presence of the unlabeled enzyme, the presence of onconase had no effect on binding ( Figure 6, top panel) . These results indicate that (À4)EDN may be binding to the same or similar cell-surface sites as onconase, causing an alteration in cellular routing or processing that results in cytotoxicity.
Intracellular processing of EDN and (À4)EDN in KS Y-1 cells
In view of the previous results, intracellular processing was examined to determine if the SLHV peptide alters the fate of EDN after binding to the cell surface (Figure 7) . Radiolabeled enzymes were incubated with KS Y-1 cells for two hours at 37 C. After removing unbound enzyme, the cells were cultured for various times and the amount of protein retained in the cells and released into the medium as intact or degraded protein was determined. Indeed, different patterns of processing were observed for each enzyme. EDN was retained longer inside KS Y-1 cells, decreasing to only about 30 % of initial levels over 30 hours. In contrast, intracellular levels of (À4)EDN decreased rapidly to about 40 % of initial levels within two hours. Furthermore, (À4)EDN was released into the medium as intact protein, whereas about 20 % of EDN was degraded. Taken together, differential processing of the two forms of EDN implies differences in intracellular compartmentalization and/or routing.
Immunofluorescence analysis of intracellular EDN and (À4)EDN
KS Y-1 cells were incubated with EDN or (À4)EDN for two hours at 37 C and processed for analysis by laser scanning confocal microscopy. Staining was greater in cells incubated with either RNase than in control cells, demonstrating visually the internalization of both enzymes (Figure 8(b) and (c) versus (a)). While predominantly nuclear localization of both EDNs was observed, EDN also localized in discrete cytoplasmic granules. Cells incubated with EDN stained more brightly than those treated with (À4)EDN, consistent with the observed greater binding of radiolabeled EDN. Moreover, as observed in the processing experiments, EDN was retained in the cells longer than (À4)EDN when the appearance and disappearance of¯uorescent proteins was followed with time (data not shown).
Conclusions
A major ®nding in this study is that the peptide extension did not change the overall conformation of native EDN. This indicates that the differences in binding and internalization that were demonstrated with (À4)EDN versus EDN are due solely C as described in Materials and Methods. Cell-associated radioactivity was determined by subtracting non-speci®c binding from total radioactivity bound. Inset: Scatchard analysis of the binding data obtained for (À4)EDN. B, bound; F, free. The speci®c activity of (À4)EDN and EDN was 2.6 Â 10 6 cpm/mg and 2.0 Â 10 6 cpm/mg, respectively.
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to the peptide recognition of a cellular marker that alters intracellular processing and/or routing, allowing (À4)EDN to access an intracellular target causing cell death. This is consistent with our previous results showing speci®c cytotoxicity of (À4)EDN 8, 9 and of antibody-targeted EDN. 29 Targeting RNase to kill cells has a counterpart in nature. In bacteria, the colicins E3 and E6 are targeted RNases that cleave the small rRNA and kill susceptible bacteria. 2, 30 In this regard, they are structurally and functionally reminiscent of RNase fusion proteins genetically engineered to target and kill diseased cells and tissues. 31 Since (À4)EDN is present in humans and inhibits oocyte maturation, a function not shared by the native enzyme, 5, 6 it is the ®rst example of a natural human targeted cytotoxic RNase. Future studies will determine the potential therapeutic use of this peptide-extended EDN and serve as a paradigm for designing other peptide-targeted RNases.
Materials and Methods
Crystallization, data collection, and structure refinement
The expression and puri®cation of (À4)EDN has been described. 8 Puri®ed enzyme was pooled and concentrated to 20 mg/ml, with crystallization performed by the hanging-drop vapor diffusion method at 22
C. Crystal screen I (Hampton Research) was used for the initial screening, whereas the ®nal crystallization condition was 100 mM sodium cacodylate (pH 6.5), 12-16 % (w/v) PEG 8 K, 150-200 mM ammonium sulfate, and 12 % (v/v) glycerol. The hanging drop was composed of 1 ml of well solution and 2 ml of protein solution. Crystals grew to the size of 0.4-0.7 mm in about ten days. They belong to the orthorhombic space group P2 1 2 1 2 1 with the unit cell parameters a 42.14 A Ê , b 52.56 A Ê , c 56.63 A Ê and with V M 1.97 A Ê 3 /Da. It needs to be noted that the crystallographic axes have been de®ned here according to the usual notation for this space group, but this de®-nition is not consistent with the usage employed for the other structures of EDN. 11, 12 A data set extending to 1.0 A Ê was collected at 100 K using the ADSC Quantum 4 CCD detector on the synchrotron beamline X9B at the National Synchrotron Light Source, Brookhaven National Laboratory, Upton, New York. Data were integrated and scaled using the HKL2000 program suite. 32 The statistics of data collection are summarized in Table 1 .
The structure of (À4)EDN was solved by molecular replacement with the program AMoRe. 33 A search model was provided by the previously solved EDN structure. 11 The fully automated script was run in the resolution range 12-3.0 A Ê , yielding the position a molecule with a correlation coef®cient of 0.285, and an R-factor of 46.4 %. The model of (À4)EDN was re®ned using SHELXL 34 at the resolution range of 20.0-1.0 A Ê . The anisotropic B-factors were re®ned for all atoms except for side-chain atoms in¯exible regions and water molecules with high temperature factors. Hydrogen The geometrical properties of the model were assessed with the program PROCHECK 36 and the secondary structure elements were assigned by the program PROMOTIF. 37 The surface charge potential was calculated by GRASP 38 and this program was used to generate surface displays. Other Figures were prepared with MOLSCRIPT 39 or Bobscript 40 and rendered with Raster3D. 41 
Ribonuclease assay
The RNase activity of EDN and (À4)EDN was determined at 37 C by monitoring the formation of perchloric acid-soluble nucleotides. 42 The following buffer was used (®nal volume of 0.3 ml); 0.16 M Tris-HCl (pH 7.5), 1.6 mM EDTA, 0.2 mg/ml of human serum albumin (HSA) (Sigma, St. Lewis, MO). Final tRNA concentrations ranged from 0.1 to 1.0 mg/ml and incubation time was 15 minutes. Each assay was repeated at least twice and the data pooled. For those assays in which the pH was varied (data not shown), the following buffers were used: for pH 6 and 6.5; 30 mM MES (pH 6.0 or 6.5), containing 0.2 mg/ml of HSA; for pH 8.0, 0.16 M Tris-HCl (pH 8.0), 1.6 mM EDTA, 0.2 mg/ml of HSA. The ®nal tRNA concentration was 0.3 mg/ml.
Protein iodination
NaPO 4 (0.2 M, pH 7.5, 50 ml) was added to 1 mCi of 125 I (Amersham Pharmacia Biotech, Piscataway, NJ) and 25 ml of this was added to each of 0.25 mg of EDN or (À4)EDN (stock concentration, 1 mg/ml). This was followed by the addition of freshly prepared chloromine T (11.5 ml of a 2 mg/ml stock solution in water) and the mixtures were incubated for ®ve minutes at room temperature. The incubation was continued for an additional minute after the addition of 23 ml of sodium metabisul®te (stock solution, 2 mg/ml in water). Each mixture was then applied to a PD10 column (Amersham Pharmacia Biotech, Piscataway, NJ) equilibrated and eluted with PBS containing 0.1 % (w/v) bovine serum albumin (BSA). The speci®c activity was 6. 24 were plated at 20,000 cells per well of a 48-well plate two days before treatment. Before use, the cells were rinsed and 100 ml of fresh medium added. Where indicated, unlabeled EDN, (À4)EDN, or onconase was added 15 minutes prior to the addition of 125 Ilabeled protein. The cells were incubated for two hours on ice, then washed twice with ice-cold PBS containing 0.1 % BSA before 100 ml of 0.1 M NaOH was added to solubilize the cells. After incubation at 37 C for 30 minutes, the contents of the wells were transferred to counting vials and the radioactivity was measured with a gamma counter. Duplicates from at least three experiments were pooled. Non-speci®c binding was determined by using a 100-fold excess of unlabeled EDN, (À4)EDN, or onconase (kindly provided by Alfacell Corp., Bloom®eld, NJ). Scatchard analysis of the (À4)EDN binding data was performed using PRISM 3. C. After washing to remove the unbound protein, the cells were cultured for varying periods ranging from two hours to 44 hours in 200 ml of culture medium at 37 C in a humidi®ed CO 2 incubator. At each time-point, 80 ml of supernatant was collected and counted (represents total released protein). To determine whether the protein found in the supernatant was degraded or intact, another aliquot of the supernatant was treated with an equal volume of cold 3.25 % (w/v) phosphotungstate in 5 % (v/v) HCl, with 0.01 mg/ml of BSA as the carrier protein. After centrifugation for 15 minutes in a microcentrifuge at top speed, the supernatant was counted (represents degraded protein). Intact protein was found in the pellet. The cells remaining in the well were solubil- C, washed and then cultured for varying times at 37 C. At the indicated time-points, the amount of protein released into the medium either intact (circles) or degraded (squares), or the amount still retained by the cells (triangles) was determined as described in Materials and Methods. Values shown are means of triplicate determinations. Standard errors of the means are shown when they are greater than the symbol. This is one of two representative experiments.
Structure and Activity of (À4)EDN ized with 0.1 M NaOH (represents retained protein). Thus, at each time-point, the percentages of retained protein and released protein were determined, the released protein being subdivided into intact and degraded protein.
Immunofluorescence studies KS Y-1 cells (25,000 cells) were plated in two-well coverglass chambers (Nalge NUNC International, Naperville, IL) pretreated with fetal bovine serum (FBS) for at least two hours at room temperature. The cells were grown for two days at 37 C in a humidi®ed CO 2 incubator to allow attachment of the cells to the glass coverslip. The cells were then washed with PBS and incubated in complete medium containing 100 mg/ml of EDN or (À4)EDN at 37 C. After two hours, the cells were washed with PBS, ®xed with 3.7 % (v/v) paraformaldehyde, permeabilized with cold methanol, and blocked with 4 % (w/v) milk/2 % BSA in PBS for 30 minutes. EDN antisera (1:500 dilution) preabsorbed with KS Y-1 cells was added to each well and the incubation continued for 60 minutes at room temperature. This was followed by washing (three times) with 1 % BSA in PBS and the addition of Alexa-labeled anti-rabbit antibody at the manufacturer's recommended dilution (Molecular Probes, Inc., Eugene, OR). After incubation for 60 minutes in the dark, the cells were rinsed with 1 % BSA in PBS (three times) and viewed with a laser scanning confocal microscope (Meridian Insight Plus, Meridian, MI).
Protein Data Bank accession code
The ®nal coordinates and the structure factors have been deposited with the RCSB Protein Data Bank under accession code 1K2A.
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